Molecular characterization of complex chromosomal changes in de novo acute myeloid leukemia: a case report
暂无分享,去创建一个
[1] L. Campbell,et al. CGH and SNP array using DNA extracted from fixed cytogenetic preparations and long-term refrigerated bone marrow specimens , 2012, Molecular Cytogenetics.
[2] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[3] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[4] B. Löwenberg,et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. , 2008, Blood.
[5] Hartmut Döhner,et al. Acute myeloid leukaemia , 2006, The Lancet.
[6] Stefan Fröhling,et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] W. Hiddemann,et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.
[8] G. Ehninger,et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia , 2003, Genes, chromosomes & cancer.
[9] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[10] D. Grimwade,et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.
[11] C. Bloomfield,et al. Clinical importance of cytogenetics in acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.
[12] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[13] J. Harousseau. Acute myeloid leukemia in the elderly. , 1998, Blood reviews.
[14] D. Kirsch,et al. Tumor-suppressor p53: implications for tumor development and prognosis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Fröhling,et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.
[16] C. Bloomfield,et al. The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes , 2009 .
[17] W. Hiddemann,et al. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia , 1997 .
[18] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.